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Ovarian granulosa cell tumor (GCT) is a malignant tumor with slow progression. The recurrence of granulosa cell
tumor often happens after 5 years, leading to a ‘forgotten tumor’ by the patient. We present the case of a
64-year-old woman with a presentation of left flank pain. An initial computed tomography scan revealed a single
tumor with multiple adjacent organ invasions. Surgical intervention was prescribed and the pathological results
revealed a metastatic granulosa cell tumor. We also review the literature for the follow-up and further management
of this tumor.Introduction
Ovarian granulosa cell tumor (GCT) is a malignant
tumor originating from the sex-cord stromal cells of the
ovary. It is an uncommon primary malignant tumor of
the ovary and represents 2% to 5% of all ovarian cancers
[1]. This tumor is classified into juvenile GCT and adult
GCT, and the majority of the cases are the adult type.
GCT occurs at any age but there are two peaks in occur-
rence: at reproductive age and postmenopausal age [2].
The incidence of GCT in women in Western countries
is twice that of women in Asia countries [3]. The clinical
symptoms of GCT are abdominal pain and abnormal va-
ginal bleeding, and some cases may also present with
menorrhagia, irregular menstruation, or amenorrhea in
the reproductive age group. GCT is a cancer with long
natural history, and recurrence often happens after
5 years of follow-up [1]. Most cases are diagnosed at
stage I disease, therefore such patients need long-term
follow-up.Case report
We present the case of a 64-year-old woman who visited
our emergency ward due to left flank pain for 1 day. She
had a history of hysterectomy and bilateral salpingo-
oophorectomy 22 years ago, but could not remember
the etiology of the primary disease due to the long time
period and being lost to follow-up after the surgery. The* Correspondence: a017749@gmail.com
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reproduction in any medium, provided the orpain was located on her left flank with radiation to the
left lower quadrant of abdomen. The pain was dull in
characteristic without aggravating factors. A physical
examination revealed a 10× 10 cm mass on the left upper
quadrant of her abdomen without local tenderness.
An 11.6 × 10.7 mass in the perirenal area was identified
on ultrasonography. Abdominal computer tomography
(CT) showed a single tumor measuring 10 × 10 cm in
the perirenal space (Figure 1). The tumor was hypervas-
cular on the arterial phase with possible gastric high
body, spleen, and pancreatic tail invasion. The differen-
tial diagnosis was metastatic tumor with unknown origin
and gastrointestinal stromal tumor of gastric origin.
Maximal debulking surgery was performed including a
splenectomy, distal pancreatecomy, partial left adrenectomy
and partial excision of the diaphragm.
The gross findings of the tumor are shown in Figure 2.
It was well encapsulated and yellowish in color. It was
friable with multiple areas of hemorrhage and necrosis.
The microscopic findings from a section of the tumor
(Figure 3) showed small round to oval tumor cells with
multiple distributive patterns, including macrofollicular,
microfollicular, diffuse and trabecullar patterns. The
tumor cells also showed scanty cytoplasm with a coffee-
bean-like nucleus. An immunohistochemical (IHC) stain
(Figure 4) was also performed to confirm diagnosis and
the IHC stain was positive for CD99, α-inhibin and
calretinin, and negative for epithelial membrane antigen
(EMA). From the hematoxylin and eosin stain and the
IHC stain results, the diagnosis of metastatic GCT was
confirmed.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdominal computer tomography (CT) showing a
single tumor measuring 20× 15 cm in the perirenal space with
spleen, pancreatic tail, and high gastric body invasion.
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GCT is an uncommon malignant tumor of the sex cord/
stromal tumor of the ovary. They only represent 2% to
5% of ovarian cancers but patients with GCT need long-
term follow-up due to the slow growth of the tumor and
long natural history of the tumor [1]. Recurrence of the
tumor usually occurs almost 5 years after first treatment
and the longest time of recurrence after treatment was
37 years [4]. The recurrence of our patient happened
22 years after the first treatment. Due to the long period
of time point and forgotten history from the patient, the
diagnosis of tumor recurrence was difficult to confirm
before the surgery. The radiological findings of the GCTFigure 2 The gross pathology of the tumor was well
encapsulated, yellowish in color, and friable with multiple
areas of hemorrhage and necrosis. The black arrow shows the
spleen; the white arrow is the pancreas tail.vary from solid mass to the cystic lesion and some may
also present hemorrhage. The two most common classi-
fications are multiseparated cystic mass and unlobulated
solid mass with cystic portions [5].
The treatments for GCT include surgical management
combined with further chemotherapy and radiation therapy.
Because of the few cases, the surgical management is based
on the treatment of other ovarian cancer. Although
total abdominal hysterectomy and bilateral salpingo-
oophorectomy is the standard treatment, for patients who
desire pregnancy, unilateral salpingo-oophorectomy can
be performed if the disease is only confined to one ovary.
For patients with recurrent tumor, aggressive debulking
surgery should be performed [6].
Adjuvant chemotherapy for GCT plays a beneficial role.
Like other ovarian cancers, platinum-based and taxane-
based chemotherapy should be considered first after
surgical resection. Although patients with stage I GCT have
an excellent prognosis and may not need chemotherapy,
patients with a large tumor size, high-grade mytosis
index and/or ruptured tumor are recommended for the
chemotherapy [7]. For patients with recurrent GCT,
chemotherapy should be prescribed to obtain better
tumor control and long survival rate. Pectasides et al.
reported combination chemotherapy with cisplatin, adria-
mycin and cyclophosphamide (CAP) for recurrent or
advanced GCT. Five complete responses and one partial
response were obtained [8].
Radiation therapy is also recommended for recurrent
GCT, especially for patients with residual tumor after
surgery. Based on the limited recurrent tumor or meta-
static cases, some small series of intense radiation therapy
for GCT have been reported to offer prolonged survival.
Wolf et al. reported 14 patients with measurable GCT
receiving radiation therapy after surgery. Complete response
was observed in 6 of 14 patients (43%). Three of them
relapsed 4 to 5 years later and the other three remain alive
without recurrence for 10 to 21 years [9].
Hormonal therapy is also a treatment choice for re-
current GCT. Hardy et al. reported a review of the
pathology for 22 GCT cases; all of the tumors were
progesterone receptor related and 32% of them were
estrogen receptor related. Several case reports also
demonstrate treatment with hormonal therapy for re-
current GCT with complete or partial response [10].
Conclusions
GCT has a low malignancy potential and long recur-
rence period. Patients with this disease at stage I
usually do not need chemotherapy after surgery.
Therefore, it would be an easily forgotten stromal cell
tumor of the ovary if the patient is not regularly fol-
lowed up. Patients with GCT require long-term fol-
low-up since recurrence usually happens 5 years after
Figure 3 Under hematoxylin and eosin stain, the tumor showed small round to oval cells with multiple distributive patterns, including
macrofollicular, microfollicular, diffuse and trabecullar patterns. The tumor cells also showed scanty cytoplasm with a coffee-bean-like
nucleus.
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specific for the diagnosis of recurrence. Estradiol and
inhibin would be elevated before the recurrence of
the GCT and can be used as markers during follow-
up. Mullerian inhibitory substance (MIS) is still under
investigation, but it could be a useful tumor marker
of GCT activity [8]. However, because of the forgot-
ten history by the patient and bizarre image findings,Figure 4 An immunohistological stain was positive for CD99, α-inhibi
epithelial membrane antigen (EMA) (sarcoma and mesenchymal tissuit usually leads to difficulty for clinicians to make an
accurate diagnosis before surgical intervention. There
is still no standard treatment for recurrent GCT, and
maximal debulking is still the best strategy. Adjuvant
radiation therapy and chemotherapy are still sug-
gested, since benefits with regard to survival are reported.
Radiation therapy should also be considered for the local
control of possible microresidual tumors.n, calretinin (sex cord stromal tumor markers) and negative for
e marker).
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Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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